Home » Newsletters » BioWorld Science

BioWorld Science

March 25, 1999

View Archived Issues

Creative BioMolecules: year-end 1998 highlights

Genzyme Tissue Repair: Q4 1998 highlights

MethylGene initiates phase I clinical trials of MG-98 for solid tumors

Cellegy reacquires Glylorin rights from Glaxo Wellcome

Verelan PM launched for management of hypertension

Dainippon's AH-9700 is an excellent candidate for treatment of urge incontinence

Gastrointestinal effects and binding profile of Taisho's 5-HT4 agonist TS-951

Bristol-Myers Squibb announces Spanish launch of antiplatelet drug

Inhibitors of MCP-1 disclosed by Zeneca for inflammation

Novo Nordisk studies compounds that interact with KATP channels

CCK-A antagonist from Zeria shows promising activity in pancreatitis models

Potassium and/or chloride channel modulators claimed for incontinence and IBS

N-type Ca2+ blockers from Warner-Lambert for neurological disorders

Hokuriku Seiyaku discusses new agents for constipation at Japanese meeting

R.W. Johnson identifies mixed adrenergic agent with analgesic activity

NIP-142: a new-concept antiarrhythmic agent is presented by Nissan Chemical

Searle characterizes new vitronectin antagonist with antitumor activity at ACS meeting

Fujisawa presents COX-2 inhibitor with potent, morphine-like analgesic effects

Novel thrombin inhibitor series from 3-D discussed at ACS meeting

GTS-21 and donepezil exert synergistic cognition-enhancing effects in rats

Lack of efficacy for lanepitant in neuropathic pain

Kampo medicine demonstrates anxiolytic efficacy in mice

LY-334370: pharmacokinetics and safety during and outside a migraine attack

Suntory presents SUN-C5174, a 5-HT2 antagonist with potent antiplatelet activity

Intranasal dosing with BMS-181885 appears feasible, according to preliminary human data

U.S. patent issues for Genzyme's pseudo-adenoviral vectors

Alpha2-agonists in development at R.W. Johnson for use as analgesics

ACS highlights: progress with GABA-modulating neuroactive steroids at CoCensys

Nonbenzamidine factor Xa inhibitors in the pipeline at Rhone-Poulenc Rorer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...